1334527-89-7

Upstream product

• 446-48-0 o-fluorobenzyl bromide 
• 851776-29-9 1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonitrile 
• 1334527-88-6 1-(2-fluorobenzyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonitrile 
• 1334527-87-5 C₁₄H₁₄FN₃O 
• 1334528-03-8 C₁₆H₁₇FN₂O₂ 

Downstream Products

• 1334527-36-4 C₁₇H₁₈FN₇ 
• 1334527-37-5 C₁₉H₂₀FN₇O₂ 
• 1334527-38-6 C₂₀H₂₂FN₇O₂ 
• 1334527-35-3 C₂₃H₂₁FN₈ 
• 1426309-13-8 4-amino-2-[1-(2-fluorobenzyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 
• 1426309-14-9 2-[1-(2-fluorobenzyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-4-iodo-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 
• 1446712-42-0 2-[1-(2-fluorobenzyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 
• 1446712-43-1 3-[1-(2-fluorobenzyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-7,7-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-e][1,2,4]triazin-6-one 
• 1446712-54-4 1-(2-fluorobenzyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboximidohydrazide 
• 1446712-55-5 methyl 2-{3-[1-(2-fluorobenzyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-5-hydroxy-1,2,4-triazin-6-yl}-2-methylpropanoate 
• 1334527-29-5 C₁₇H₁₆FN₅ 

Relevant academic research and scientific papers

Substituted fused imidazoles and pyrazoles and use thereof

The present application relates to novel substituted fused imidazoles and pyrazoles, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof producing medicame

Substituted annellated pyrimidines and use thereof

The present application relates to novel substituted annellated pyrimidines, methods for production thereof, use thereof alone or in combinations for treating and/or preventing diseases and use thereof for the production of medicinal products for treating

SUBSTITUTED CYCLOALKENOPYRAZOLES AS BUB1 INHIBITORS FOR THE TREATMENT OF CANCER

Compounds of formula (I), processes for their production and their use as Bubl kinase inhibitors for the treatment of hyperproliferative diseases and/or disorders responsive to induction of cell death.

SGC STIMULATORS

Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.